| Price | 1,945.50p on 04-02-2026 at 06:00:05 |
|---|---|
| Change | 0.00p 0% |
| Buy | 1,948.00p |
| Sell | 1,770.00p |
| Last Trade: | Buy 601.00 at 1,945.50p |
| Day's Volume: | 0 |
| Last Close: | 1,945.50p |
| Open: | 0.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 1,242.50p - 1,945.50p |
| Market Capitalisation: | £78.50b |
| VWAP: | 0.00p |
| Shares in Issue: | 4.03b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 601 | 1,945.50p | SI Trade Negotiated Trade |
16:48:12 - 03-Feb-26 |
| Buy* | 1,500 | 1,945.50p | Automatic Execution |
16:39:53 - 03-Feb-26 |
| Buy* | 1,500 | 1,945.50p | Automatic Execution |
16:35:15 - 03-Feb-26 |
| Buy* | 3,715 | 1,945.50p | SI Trade |
16:35:10 - 03-Feb-26 |
| Buy* | 2,688,831 | 1,945.50p | Suspected BUY Trade |
16:35:10 - 03-Feb-26 |
| Unknown* | 0 | 1,942.50p | SI Trade |
16:29:55 - 03-Feb-26 |
| Sell* | 100 | 1,941.82p | Negotiated Trade |
16:29:52 - 03-Feb-26 |
| Buy* | 263 | 1,942.50p | SI Trade |
16:29:50 - 03-Feb-26 |
| Buy* | 550 | 1,942.00p | Automatic Execution |
16:29:50 - 03-Feb-26 |
| Buy* | 400 | 1,942.00p | Automatic Execution |
16:29:50 - 03-Feb-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 2nd Feb 2026 3:00 pm | RNS | Total Voting Rights |
| 26th Jan 2026 7:00 am | RNS | European Commission approves Arexvy for adults 18+ |
| 20th Jan 2026 7:05 am | RNS | GSK to acquire RAPT Therapeutics |
| 20th Jan 2026 7:00 am | RNS | Agreement on changes to ViiV minority shareholding |
| 16th Jan 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 15th Jan 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 13th Jan 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 7th Jan 2026 7:05 am | RNS | EC approval of Shingrix PFS |
| 7th Jan 2026 7:00 am | RNS | Positive phase 3 data for GSK's bepirovirsen |
| 6th Jan 2026 7:00 am | RNS | Exdensur approved in Japan |
